with the vitamins. Nobelprize.org. 4. Keys, A. (1953). Atherosclerosis: a problem in newer public health. Journal of Mount Sinai Hospital, 20(2), 118-139. 5. Gofman, J. W., et al. (1950). Lipoproteins, coronary heart disease, and atherosclerosis. Physiological Reviews, 30(4), 241-346. 6. Brown, M. S., & Goldstein, J. L. (1986). A receptor-mediated pathway for cholesterol homeostasis. Science, 232(4746), 34-47. 7. Endo, A. (1979). Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors. Klinische Wochenschrift, 57(11), 1127-1132. 8. Sabatine, M. S., et al. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine, 376(18), 1713-1722. 9. Abifadel, M., et al. (2003). Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics, 34(2), 154-156. 10. Berger, S., et al. (2015). Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. American Journal of Clinical Nutrition, 102(2), 276-294. 11. Mozaffarian, D., et al. (2010). Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Medicine, 7(3), e1000252. 12. Dawber, T. R., et al. (1951). Epidemiological approaches to heart disease: the Framingham Study. American Journal of Public Health, 41(3), 279-286. 13. Hansson, G. K. (2005). Inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine, 352(16), 1685-1695. 14. Residual Risk Reduction Initiative (R3I). (2010). Addressing residual risk beyond LDL cholesterol. Atherosclerosis Supplements, 11(1), 1-5. 15. Wang, Z., et al. (2011). Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature, 472(7341), 5763. Kapitola: Od objevu k moderní medicíně 800 182 572 7:30-16:30 (Pá: do14:00) Vyhlídka 39, 63800 Brno, Česká republika Tel: +420 545 222 863 Fax: +420 545 222 011 www.vitaminy-mineraly.cz Strana 6
RkJQdWJsaXNoZXIy Nzg5MDg=